Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA4 | P22748 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12147645 | 0.93 | TSHR (0.47) | TSHRCES2MEN1KMT2AGLP1R | |
| SCHEMBL16478824 | 0.90 | TSHR (0.45) | TSHRCES2GLP1R | |
| SCHEMBL24484088 | 0.89 | CES2 (0.51) | TSHRCES2GLP1RCNR1 | |
| SCHEMBL22198374 | 0.88 | TSHR (0.52) | TSHRMEN1KMT2AGLP1RCA12 | |
| SCHEMBL19369668 | 0.88 | GLP1R (0.44) | TSHRCES2MEN1KMT2AGLP1R | |
| SCHEMBL26020180 | 0.87 | CES2 (0.54) | CES2GLP1RCNR1 | |
| SCHEMBL13255985 | 0.87 | TSHR (0.47) | TSHRMEN1KMT2AGLP1RCA12 | |
| SCHEMBL24253207 | 0.86 | TSHR (0.44) | TSHRCES2MEN1KMT2AGLP1R | |
| SCHEMBL23729785 | 0.86 | SMN1; SMN2 (0.50) | TSHRCES2GLP1RSMN1; SMN2 | |
| SCHEMBL12666120 | 0.86 | GLP1R (0.47) | TSHRCES2GLP1RCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017204445-A2 | PHARMACEUTICAL COMPOSITION INDUCING DECOMPOSITION OF ALK PROTEIN, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE COMPONENT | 한국화학연구원 | 2017-11-30 | — | — | WO | disclosed |
| US-20140205545-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | DYAX CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8663603-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2014-03-04 | — | — | US | disclosed |
| US-8632753-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2014-01-21 | — | — | US | disclosed |
| US-20110286929-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2011-11-24 | — | — | US | disclosed |
| US-7261876-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL BV (NL) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140205545-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | TSHR 2125/4885CES2 2949/4885MEN1 202/4885 |
| US-20110286929-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | TSHR 2125/4885CES2 2949/4885MEN1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.